What We're Reading: Page 4
Industry reads hand-picked by our editors
Feb 28, 2024
-
Bloomberg
US Data Security Order To Limit China’s Access to Americans’ Personal Data
-
MIT Technology Review
Tackling long-haul diseases
-
Fierce Biotech
AbbVie pays $48M for OSE’s preclinical chronic inflammation drug
Feb 27, 2024
Feb 26, 2024
-
Fierce Biotech
J&J to close Bay Area R&D site less than 18 months after opening
-
The Denver Post
Enbrel price cap OK’d by Colorado Prescription Drug Affordability Board
-
The Pharma Letter
FDA issues final decision to withdraw Pepaxto accelerated approval
-
The New York Times
Drug Drastically Reduces Children’s Reactions to Traces of Food Allergens
Feb 23, 2024
-
Science
A deadly viral illness is exploding in West Africa. Researchers are scrambling to figure out why
-
Reuters
US bill on Chinese biotech firms may be more ‘narrowly tailored’, lawmaker says
-
Fierce Biotech
GSK, Vir end flu drug alliance, removing key piece of $345M pact
-
New York Magazine
The Empty Adderall Factory
Feb 22, 2024
-
BioSpace
PhRMA Names Gilead CEO O’Day as New Board Chair Following Loss of Members
-
Reuters
Emergent appoints former Bausch + Lomb CEO to head company
-
Axios
Alabama Supreme Court ruling adds to legal uncertainty around IVF
-
Wired
Neuralink’s First Brain Implant Is Working. Elon Musk’s Transparency Isn’t